Menu
Back to Journals » ImmunoTargets and Therapy » Volume 4
ImmunoTargets and Therapy
ISSN: 2253-1556
- View all (170)
- Volume 13, 2024 (15)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Archive: Volume 4, 2015
Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
Cauli A, Piga M, Floris A, Mathieu A
ImmunoTargets and Therapy 2015, 4:185-190
Published Date: 1 October 2015
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
Shah S, Geetha D
ImmunoTargets and Therapy 2015, 4:173-183
Published Date: 7 August 2015
The role of regulatory T cells in cancer immunology
Whiteside TL
ImmunoTargets and Therapy 2015, 4:159-171
Published Date: 5 August 2015
The hygiene hypothesis: current perspectives and future therapies
Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB
ImmunoTargets and Therapy 2015, 4:143-157
Published Date: 27 July 2015
Novel perspectives on non-canonical inflammasome activation
Diamond CE, Khameneh HJ, Brough D, Mortellaro A
ImmunoTargets and Therapy 2015, 4:131-141
Published Date: 24 July 2015
Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy
Altabas V, Zjačić-Rotkvić V
ImmunoTargets and Therapy 2015, 4:123-130
Published Date: 9 July 2015
CD28 co-stimulation in T-cell homeostasis: a recent perspective
Beyersdorf N, Kerkau T, Hünig T
ImmunoTargets and Therapy 2015, 4:111-122
Published Date: 28 May 2015
Emerging roles for HMGB1 protein in immunity, inflammation, and cancer
Martinotti S, Patrone M, Ranzato E
ImmunoTargets and Therapy 2015, 4:101-109
Published Date: 26 May 2015
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE
ImmunoTargets and Therapy 2015, 4:91-100
Published Date: 15 May 2015
Update on use of aldesleukin for treatment of high-risk metastatic melanoma
Amaria RN, Reuben A, Cooper ZA, Wargo JA
ImmunoTargets and Therapy 2015, 4:79-89
Published Date: 7 April 2015
Emerging role of Natural killer cells in oncolytic virotherapy
Bhat R, Rommelaere J
ImmunoTargets and Therapy 2015, 4:65-77
Published Date: 31 March 2015
Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
Perna SK, Huye LE, Savoldo B
ImmunoTargets and Therapy 2015, 4:55-63
Published Date: 19 March 2015
Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors
Thomas LM
ImmunoTargets and Therapy 2015, 4:45-53
Published Date: 16 March 2015
Development of antibody-based c-Met inhibitors for targeted cancer therapy
Lee D, Sung ES, Ahn JH, An S, Huh J, You WK
ImmunoTargets and Therapy 2015, 4:35-44
Published Date: 9 February 2015
Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?
Kohyama K, Matsumoto Y
ImmunoTargets and Therapy 2015, 4:27-34
Published Date: 8 January 2015
The role of autophagy in microbial infection and immunity
Desai M, Fang R, Sun J
ImmunoTargets and Therapy 2015, 4:13-26
Published Date: 6 January 2015
Antigen-based immunotherapy for autoimmune disease: current status
Hirsch DL, Ponda P
ImmunoTargets and Therapy 2015, 4:1-11
Published Date: 16 December 2014